title: Villoglandular adenocarcinoma of the endometrium: a clinicopathologic study of 61 cases: a gynecologic oncology group study.
abstract: Papillary endometrioid or villoglandular adenocarcinoma (VGA) is a relatively common type of endometrial adenocarcinoma, but studies describing its behavior have yielded conflicting results. Patients with a component of VGA were identified in a review of 819 women entered in a Gynecology Oncology Group Study (Protocol 33) of clinical stages I and II endometrial adenocarcinoma. Cases with coexisting foci of serous or clear cell carcinoma were excluded from further consideration. Of the 61 cases that formed the study sample, there were 24 with pure villoglandular differentiation and 37 who were admixed with typical endometrioid adenocarcinoma (EA). The general clinicopathologic features of patients with pure and mixed VGA are compared with 469 patients with pure EA. The VGAs were better differentiated (grade 1 or 2--97% of VGA versus 74% EA, p = 0.001). but they were not significantly different with respect to median age, depth of invasion, or frequency of nodal spread. Six of the 61 patients with VGA died of their tumor. The disease-specific survival rate at 3 years for VGA is 94% (95% confidence interval: 0.88-0.99) compared with 88% (95% CI: 0.86-0.91) for EA. Two of the patients who died had pure villoglandular tumors and four had mixed villoglandular and endometrioid carcinoma. In view of the frequent admixture of VGA and EA and their generally similar biological characteristics, with a prognosis similar to that of typical EA, we conclude that VGA should be considered a variant of EA.
authors.affiliation: Department of Pathology, The Milton S. Hershey Medical Center of Pennsylvania State University, Hershey 17033, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Zaino
authors.forename: R J
authors.initials: RJ
authors.lastname: Kurman
authors.forename: V L
authors.initials: VL
authors.lastname: Brunetto
authors.forename: C P
authors.initials: CP
authors.lastname: Morrow
authors.forename: R C
authors.initials: RC
authors.lastname: Bentley
authors.forename: J O
authors.initials: JO
authors.lastname: Cappellari
authors.forename: P
authors.initials: P
authors.lastname: Bitterman
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000145:classification / Q000473:pathology; D000231:Adenocarcinoma, Papillary / Q000145:classification / Q000401:mortality / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018269:Carcinoma, Endometrioid / Q000145:classification / Q000401:mortality / Q000473:pathology*; D018283:Cystadenocarcinoma, Papillary / Q000145:classification / Q000473:pathology; D003937:Diagnosis, Differential; D016889:Endometrial Neoplasms / Q000145:classification / Q000401:mortality / Q000473:pathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies; D015996:Survival Rate